Condition
Endometrial Transitional Cell Carcinoma
Total Trials
5
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Completed4
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02834013Phase 2Active Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT01440998Phase 1Completed
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT01642082Phase 2Completed
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00888173Phase 2Completed
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887Phase 2Completed
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Showing all 5 trials